-

Ferrer Allocates, on Average, More Than 40% of its Profits to Social and Environmental Projects for the Third Consecutive Year

BARCELONA, Spain--(BUSINESS WIRE)--The pharmaceutical company Ferrer, certified as a B Corp in 2022, has again shown that there is another way of doing business, with an ethical business approach that contributes to a better society. Over the past three years, Ferrer has allocated over 40% on average of its net profits to various social and environmental projects aimed at creating a fairer and more equitable society. As stated in the company’s Sustainability Report, in 2022, 47% of profits were reinvested, carrying out the company's commitment to making a positive impact in society.

"As a company, we have an obligation and responsibility to put business profitability and social benefit on an equal footing. We believe that the pharmaceutical business is not an end in itself, but a means to generate substantial social change. We are aware that we still have a long way to go, but we want to encourage other companies to follow the same path," says Mario Rovirosa, Ferrer’s CEO.

To inspire other companies and extend the positive impact beyond Ferrer itself, various initiatives have been launched involving business partners, suppliers and other companies. The Suppliers for Good program is an example in which Ferrer aims to support and guide its suppliers in improving their Environmental, Social and Governance (ESG) practices. An ESG evaluation process for suppliers was launched, and by 2022, 320 suppliers had already been evaluated through the Ecovadis platform, including nearly 50% of suppliers identified as significant. As a result, in 2022 the company was recognized as a leader in Carbon Disclosure Project Supplier Engagement. As a further consequence of this initiative, Ferrer has been certified EcoVadis Gold.

A similar project has also been launched to involve business partners, called Partners for Good. The project consists of evaluating and promoting environmental, social and corporate governance performance among selected partners and defining actions to support and involve them in making a positive impact in society.

Contacts

Ferrer
asendin@ferrer.com
Tel.: +34 936 003 779

GRUPO FERRER INTERNACIONAL, SA.

Details
Headquarters: Barcelona, Spain
CEO: Mario Rovirosa
Employees: 1.800
Organization: PRI


Contacts

Ferrer
asendin@ferrer.com
Tel.: +34 936 003 779

More News From GRUPO FERRER INTERNACIONAL, SA.

Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp

BARCELONA, Spain--(BUSINESS WIRE)--Spanish pharmaceutical company Ferrer has reaffirmed its status as a B Corp, an international certification awarded to companies that operate with a business model centered on positive impact and meet high social, environmental, and community standards. Ferrer has achieved a score of 136.4 points, making it the highest-rated pharmaceutical company in the world. Additionally, it now ranks as the third-highest scoring company across all sectors globally among th...

Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer has achieved Compliance Leader Verification™, the prestigious recognition granted by Ethisphere, which distinguishes the pharmaceutical company as a global leader in upholding ethical and responsible corporate practices in its business operations. Ethisphere is a leading organization dedicated to advancing ethical business practices, and its recognition acknowledges organizations with an outstanding commitment to robust ethics and compliance programs. T...

The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

MADRID--(BUSINESS WIRE)--The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines1. This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This...
Back to Newsroom